At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNM Immunome Inc.
Trading 08-20 11:24:06 EDT
28.59
-1.23
-4.14%
High29.13Low28.27Vol230.58K
Open29.13D1 Closing29.83Amplitude2.88%
Mkt Cap3.25BTradable Cap3.09BTotal Shares113.58M
T/O6.61MT/O Rate0.21%Tradable Shares108.11M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says
MT Newswires Live  ·  08-18 22:54
Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration
Simply Wall St.  ·  08-18 17:20
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration
argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM
TIPRANKS  ·  08-17
argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
GlobeNewswire  ·  08-17
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027
Reuters  ·  08-14
Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027
Replimune Q1 Net Loss Narrows as Expenses Decline
Reuters  ·  08-14
Replimune Q1 Net Loss Narrows as Expenses Decline
Allarity Therapeutics Q2 Loss Narrows as Expenses Fall
Reuters  ·  08-14
Allarity Therapeutics Q2 Loss Narrows as Expenses Fall
Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses
Reuters  ·  08-14
Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses
Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses
Reuters  ·  08-14
Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses
NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
Reuters  ·  08-14
NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall
Reuters  ·  08-14
Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall
PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall
Reuters  ·  08-13
PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall
Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs
Reuters  ·  08-13
Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs
Immunome Director Isaac Barchas Reports Disposal of Common Shares Worth $2.18 Million
Reuters  ·  08-13
Immunome Director Isaac Barchas Reports Disposal of Common Shares Worth $2.18 Million
Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook
Reuters  ·  08-13
Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook
Immunome Price Target Raised to $35.00/Share from $31.00 by Wedbush
Dow Jones  ·  08-13
Immunome Price Target Raised to $35.00/Share from $31.00 by Wedbush
Evercore ISI Remains a Buy on Immunome (IMNM)
TIPRANKS  ·  08-12
Evercore ISI Remains a Buy on Immunome (IMNM)
Immunome, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Immunome, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
TIPRANKS  ·  08-12
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
Wedbush Adjusts Price Target on Immunome to $35 From $31, Keeps Outperform Rating
MT Newswires Live  ·  08-12
Wedbush Adjusts Price Target on Immunome to $35 From $31, Keeps Outperform Rating
No data available

Introduction

Company Name.
Immunome Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Issue price:
--